ClinicalTrials.gg
CompletedNCT03287960Updated May 23, 2023Results posted

Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity

A Phase 3 interventional study of Setmelanotide and Placebo in Leptin Receptor Deficiency Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 6 sites in 6 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2023-05-23.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.

Enrollment
11th of 16
15 · median 34
Started
2018
with 2 others
Phase 3
6 of 16
none open now
Registered
8th of 16
by date
Lead sponsor
15 of 16
Rhythm Pharmaceuticals, Inc.

Among the 16 studies testing setmelanotide in Obesity, this one is the 11th largest by enrollment, is one of 3 that started in 2018, is one of 6 in phase 3, and was the 8th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About setmelanotide

setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing setmelanotide in Obesity, or all of them as a file.
02

Study summary

To demonstrate statistically significant and clinically meaningful effects of setmelanotide on percent body weight change in participants with LEPR deficiency obesity due to rare bi-allelic or loss-of function mutations at the end of 1 year of treatment.

03

Conditions studied

  • Leptin Receptor Deficiency Obesity

Browse trials for

Keywords

  • LEPR deficiency obesity
  • setmelanotide
  • RM-493
  • Leptin receptor
  • Obesity
  • Melanocortin 4 receptor
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Bi-allelic, homozygous or compound heterozygous (a different gene mutation on each allele) genetic status for the LEPR gene, with the loss-of-function (LOF) variant for each allele conferring a severe obesity phenotype.
  2. Age 6 years and above. 6+: Germany, Netherlands, UK. 12+: France
  3. If adult age ≥18 years, obesity with (BMI) ≥ 30 kilograms per meters squared (kg/m\^2); if child or adolescent (\< 18 years of age), obesity with weight > 97th percentile for age on growth chart assessment.
  4. Study participant and/or parent or guardian is able to communicate well with the investigator, to understand and comply with the requirements of the study, and is able to understand and sign the written /assent, after being informed about the study.
  5. Female participants of must agree to use as outlined in the protocol. Female participants of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) for at least 12 months (and confirmed with a screening FSH level in the post-menopausal lab range), or failure to have progressed to Tanner Stage V and/or failure to have achieved menarche, do not require contraception during the study.
  6. Male participants with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study. Male participants must not donate sperm during and for 90 days following their participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. Recent intensive (within 2 months) diet and/or exercise regimen with or without the use of weight loss agents including herbal medications, that has resulted in weight loss or weight stabilization.
  2. Prior gastric bypass surgery resulting in >10% weight loss durably maintained from the baseline pre-operative weight with no evidence of weight regain.
  3. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other (DSM-III) disorders that the investigator believes will interfere significantly with study compliance.
  4. A Patient Health Questionnaire-9 (PHQ-9) score of ≥ 15.
  5. Any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS). Any lifetime history of a suicide attempt, or any suicidal behavior in the last month.
  6. Current, severe stable restrictive or obstructive lung disease arising because of extreme obesity, evidence of significant heart failure ( [NYHA] Class 3 or greater), or oncologic disease, if these were severe enough to interfere with the study and/or would confound the results.
  7. History of significant liver disease or liver injury, or current liver assessment for a cause of abnormal liver tests [as indicated by abnormal liver function tests, (ALT), aspartate transaminase (AST), alkaline phosphatase, or serum (> 2.0 x (ULN) for any of these tests)] for an etiology other than non-alcoholic fatty liver disease (NAFLD).
  8. History or presence of impaired renal function as indicated by abnormal creatinine, blood urea nitrogen (BUN), or urinary constituents (e.g., albuminuria) or moderate to severe renal dysfunction as defined by the equation \< 30 milliliter/minute (mL/min).
  9. History or close family history (parents or siblings) of skin cancer or melanoma, or participant history of ocular-cutaneous albinism.
  10. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions, determined as part of a screening comprehensive skin evaluation performed by a qualified dermatologist.
  11. Volunteer is, in the opinion of the study investigator, not suitable to participate in the study.
  12. Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing.
  13. Significant to study drug.
  14. Inability to comply with every day (QD) injection regimen.
  15. Participants who have been placed in an institution through an official or court order, as well as those who are dependent on the sponsor, Investigator or study site.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Setmelanotide

    Participants received titrated doses of setmelanotide once daily, by SC injection during titration period for 2 - 12 weeks. Thereafter, participants continued setmelanotide at their specific therapeutic dose for an additional 10 weeks during the open label treatment period. Participants who achieved at least a 5 kg weight loss (or at least 5% weight loss if baseline body weight was \<100 kg) at the end of the open label treatment period, continued into the 8-week double-blind withdrawal period and received 4 weeks setmelanotide and 4 weeks placebo. Following the withdrawal period, participants entered open label treatment period and received setmelanotide to complete approximately 52 weeks (\~1 year) of treatment at a therapeutic dose.

    Drug: Setmelanotide · Drug: Placebo

Interventions

  • Once daily subcutaneous injection

    Also known as: RM-493

  • DrugPlacebo

    Once daily subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)

    The percentage of participants who met the ≥10% weight loss threshold (responders) after approximately Week 52 (\~1 year) of treatment were analyzed.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort)

    The percentage of participants who met the ≥10% weight loss threshold (responders) after approximately Week 52 (\~1 year) of treatment were analyzed.

    Time frame: Week 52

  2. Mean Percent Change From Baseline in Body Weight

    The mean percent change from baseline in body weight at 52 weeks was analyzed.

    Time frame: Baseline and Week 52

  3. Mean Percent Change From Baseline in Hunger Score ('Most Hunger')

    The mean percent change in hunger scores for participants ≥12 years of age with leptin receptor (LEPR) deficiency obesity in treatment with setmelanotide was evaluated. Hunger score ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis.

    Time frame: Baseline and Week 52

  4. Percentage of Participants Achieving at Least 25% Improvement in Daily Hunger From Baseline

    The percentage of participants (≥12 years of age) achieving a ≥25% improvement from baseline in hunger score at Week 52 (i.e., after treatment with setmelanotide for 52 weeks at the therapeutic dose) was assessed. Hunger ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis.

    Time frame: Baseline and Week 52

  5. Absolute Change From Baseline in Waist Circumference

    Waist circumference (cm) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Waist circumference was measured when participants were fasting at approximately the same time at each visit. The absolute change from baseline in waist circumference was assessed.

    Time frame: Baseline and Week 52

  6. Absolute Change in Body Weight (Reversal of Weight Loss) During Double-Blind Placebo-Controlled Withdrawal Period

    A comparison of weight change was evaluated during the 8 week placebo-controlled withdrawal period for each participant, during which each participant received 4 weeks of placebo and 4 weeks active therapy in a blinded fashion.

    Time frame: Baseline and Week 8 of withdrawal period

  7. Absolute Daily Hunger Reduction Score During the Double-Blind Placebo-Controlled Withdrawal Period

    The absolute score in daily hunger reduction during the double-blind placebo-controlled withdrawal period (≥12 Years of Age) was assessed. Hunger ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis. The weekly average hunger score of the daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint. Lower scores represent lower hunger, higher scores represent greater hunger.

    Time frame: Week 8 of withdrawal period

  8. Mean Percent Change From Baseline in Body Mass Index

    The mean percent change from baseline in body mass index (BMI) was assessed.

    Time frame: Baseline and Week 52

  9. Change From Baseline in Glucose Parameters

    Glucose parameters included glucose, glycated hemoglobin (HbA1c) and Oral glucose tolerance test (OGTT). Data is planned to be reported only for change from baseline in glucose levels.

    Time frame: Baseline and Week 52

07

Results

Posted May 23, 2023
Limitations and caveats
Based on meetings with the Federal Drug Administration (FDA), the structure of the endpoints was slightly different in the statistical analysis plan (SAP) and the protocol. In addition, there was no planned comparison to a randomized placebo group given the rarity of monogenic LEPR deficiency obesity.

Participant flow

Participants were enrolled into the pivotal cohort (11 participants) or supplemental cohort (4 participants). Pivotal cohort: Set of participants under study constituted a collection of detailed clinical case reports with a comprehensive baseline and past medical history assessment and complete clinical efficacy, safety and laboratory evaluations conducted for each participant. Supplemental cohort: Any additional participants enrolled were included in supplemental cohort.

Titration Period (2 to 12 Weeks)
Participant flow — Titration Period (2 to 12 Weeks)
MilestoneSetmelanotide
Started15
Completed15
Not completed0
Open-Label Period (10 Weeks)
Participant flow — Open-Label Period (10 Weeks)
MilestoneSetmelanotide
Started15
Completed14
Not completed1
Withdrew: Adverse event1
Double-Blind Withdrawal Period (8 Weeks)
Participant flow — Double-Blind Withdrawal Period (8 Weeks)
MilestoneSetmelanotide
Started14
Completed14
Not completed0
Open-Label Period (32 Weeks)
Participant flow — Open-Label Period (32 Weeks)
MilestoneSetmelanotide
Started14
Completed13
Not completed1
Withdrew: Serious adverse event1

Outcome measures

PrimaryPercentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)

The percentage of participants who met the ≥10% weight loss threshold (responders) after approximately Week 52 (\~1 year) of treatment were analyzed.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)
percentage of participantsSetmelanotide (Entire Study)
Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)45.5 (19.96 to 72.88)
Statistical analysis
  • Setmelanotide (Entire Study) · Clopper-Pearson method · p = 0.0001
SecondaryPercentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort)

The percentage of participants who met the ≥10% weight loss threshold (responders) after approximately Week 52 (\~1 year) of treatment were analyzed.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort)
percentage of participantsSetmelanotide (Entire Study)
Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort)53.3 (30.00 to 75.63)
Statistical analysis
  • Setmelanotide (Entire Study) · Clopper-Pearson method · p = <0.0001
SecondaryMean Percent Change From Baseline in Body Weight

The mean percent change from baseline in body weight at 52 weeks was analyzed.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Body Weight
Percent changeSetmelanotide (Entire Study)
Mean Percent Change From Baseline in Body Weight-12.34 ± 7.534
Statistical analysis
  • Setmelanotide (Entire Study) · ANOVA · p = <.0001 · Least squares mean: -12.37 · 90% CI -15.08 to -9.66Longitudinal mixed ANOVA
SecondaryMean Percent Change From Baseline in Hunger Score ('Most Hunger')

The mean percent change in hunger scores for participants ≥12 years of age with leptin receptor (LEPR) deficiency obesity in treatment with setmelanotide was evaluated. Hunger score ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percent Change
Mean Percent Change From Baseline in Hunger Score ('Most Hunger')
Percent ChangeSetmelanotide (Entire Study)
Mean Percent Change From Baseline in Hunger Score ('Most Hunger')-42.7 ± 27.49
Statistical analysis
  • Setmelanotide (Entire Study) · ANOVA · p = <.0001 · Least squares mean: -42.69 · 90% CI -56.35 to -29.02Longitudinal mixed analysis of variance (ANOVA) model
SecondaryPercentage of Participants Achieving at Least 25% Improvement in Daily Hunger From Baseline

The percentage of participants (≥12 years of age) achieving a ≥25% improvement from baseline in hunger score at Week 52 (i.e., after treatment with setmelanotide for 52 weeks at the therapeutic dose) was assessed. Hunger ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least 25% Improvement in Daily Hunger From Baseline
percentage of participantsSetmelanotide (Entire Study)
Percentage of Participants Achieving at Least 25% Improvement in Daily Hunger From Baseline71.4 (46.00 to 89.60)
Statistical analysis
  • Setmelanotide (Entire Study) · Clopper-Pearson method · p = <.0001
SecondaryAbsolute Change From Baseline in Waist Circumference

Waist circumference (cm) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Waist circumference was measured when participants were fasting at approximately the same time at each visit. The absolute change from baseline in waist circumference was assessed.

Time frame:
Baseline and Week 52
Reported as:
Mean · Centimeter
Absolute Change From Baseline in Waist Circumference
CentimeterSetmelanotide (Entire Study)
Baseline131.58 ± 24.047
Change at Week 52-9.80 ± 6.095
Statistical analysis
  • Setmelanotide (Entire Study) · ANOVA · p = 0.0031 · Least squares mean: -8.9 · 90% CI -14.10 to -3.61Longitudinal mixed ANOVA
SecondaryAbsolute Change in Body Weight (Reversal of Weight Loss) During Double-Blind Placebo-Controlled Withdrawal Period

A comparison of weight change was evaluated during the 8 week placebo-controlled withdrawal period for each participant, during which each participant received 4 weeks of placebo and 4 weeks active therapy in a blinded fashion.

Time frame:
Baseline and Week 8 of withdrawal period
Reported as:
Mean · Kilogram
Absolute Change in Body Weight (Reversal of Weight Loss) During Double-Blind Placebo-Controlled Withdrawal Period
KilogramSetmelanotide (Double-Blind)
Change at Week 4: Setmelanotide-1.2 ± 3.04
Change at Week 4: Placebo4.9 ± 2.82
SecondaryAbsolute Daily Hunger Reduction Score During the Double-Blind Placebo-Controlled Withdrawal Period

The absolute score in daily hunger reduction during the double-blind placebo-controlled withdrawal period (≥12 Years of Age) was assessed. Hunger ranged from 0 - 10 on a Likert-type scale; 0 = not hungry at all and 10 = hungriest possible. On the Daily Hunger Questionnaire, each of the 3 items (average hunger, most/worst hunger, and morning hunger) was scored separately and averaged on a weekly basis. The weekly average hunger score of the daily worst (most) hunger score in 24 hours is the hunger score used to assess this study endpoint. Lower scores represent lower hunger, higher scores represent greater hunger.

Time frame:
Week 8 of withdrawal period
Reported as:
Mean · units on a scale
Absolute Daily Hunger Reduction Score During the Double-Blind Placebo-Controlled Withdrawal Period
units on a scaleSetmelanotide (Double-Blind)
Setmelanotide3.4 ± 1.63
Placebo6.3 ± 2.13
SecondaryMean Percent Change From Baseline in Body Mass Index

The mean percent change from baseline in body mass index (BMI) was assessed.

Time frame:
Baseline and Week 52
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Body Mass Index
Percent changeSetmelanotide (Entire Study)
Mean Percent Change From Baseline in Body Mass Index-14.24 ± 9.096
Statistical analysis
  • Setmelanotide (Entire Study) · ANOVA · p = <.0001 · Least squares mean: -14.0 · 90% CI -16.80 to -11.20Longitudinal mixed ANOVA model
SecondaryChange From Baseline in Glucose Parameters

Glucose parameters included glucose, glycated hemoglobin (HbA1c) and Oral glucose tolerance test (OGTT). Data is planned to be reported only for change from baseline in glucose levels.

Time frame:
Baseline and Week 52
Reported as:
Mean · millimole per liter
Change From Baseline in Glucose Parameters
millimole per literSetmelanotide (Entire Study)
Baseline5.586 ± 2.3740
Change at Week 52-0.465 ± 1.4350

Adverse events

Collected over From first dose up to ~30 days after last dose of study drug (Up to ~ 1 year). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Setmelanotide1/15 (6.7%)3/15 (20%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventSetmelanotide
CholecystitisHepatobiliary disorders1/15
Road Traffic AccidentInjury, poisoning and procedural complications1/15
Suicidal IdeationPsychiatric disorders1/15
Gastric Banding ReversalSurgical and medical procedures1/15
Most frequent other events
Showing 10 of 132
Most frequent other events
EventSetmelanotide
Injection site erythemaGeneral disorders11/15
Skin hyperpigmentationSkin and subcutaneous tissue disorders11/15
Injection site pruritusGeneral disorders8/15
NauseaGastrointestinal disorders8/15
Injection site indurationGeneral disorders7/15
Injection site painGeneral disorders7/15
DiarrheaGastrointestinal disorders7/15
Injection site oedemaGeneral disorders6/15
Injection site bruisingGeneral disorders5/15
HeadacheNervous system disorders5/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Setmelanotide
<=18 years5
Between 18 and 65 years10
>=65 years0
Age, Continuous
Age, Continuous(years)Setmelanotide
Mean21.67 ± 8.52
Sex: Female, Male
Sex: Female, Male(Participants)Setmelanotide
Female9
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Setmelanotide
Hispanic or Latino0
Not Hispanic or Latino13
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Setmelanotide
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(Participants)Setmelanotide
Netherlands3
United Kingdom1
France6
Germany4
Canada1
08

Study locations

6 sites
  • Markham Stouffville Hospital
    Markham, Ontario L3P 7P3, Canada
  • Institute of Cardiometabolism and Nutrition / Pitié-Salpêtrière Hospital
    Paris, 75013, France
  • University of Ulm
    Ulm, Germany
  • Erasmus Medical Center
    Rotterdam, Netherlands
  • Hôpital Félix GUYON
    Saint Denis, 97405, Réunion
  • University of Cambridge Metabolic Research Laboratories
    Cambridge, CB2 0QQ, United Kingdom
09

References and documents

Publications

  • Clement K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kuhnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30. PubMed 33137293 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Sep 2020, 31 months.

Results were first posted in May 2023, 2 years 7 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 31 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2017
First posted
Sep 19, 2017
StartActual
Jan 30, 2018
Primary completionActual
Sep 25, 2020
CompletionActual
Sep 25, 2020
Results first posted
May 23, 2023
Last update
May 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03287960
Responsible party
Sponsor
First posted
Sep 19, 2017
Start date
Jan 30, 2018
Primary completion
Sep 25, 2020
Completion
Sep 25, 2020
Results posted
May 23, 2023
Last update
May 23, 2023

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion